Ladenburg Thalmann Financial Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$3.71M	Buy	66,345 +225	+0.3%	+$11.7K	0.02%	598
2019 Q3	$3.13M	Buy	66,120 +153	+0.2%	+$7.84K	0.02%	637
2019 Q2	$3.53M	Sell	65,967 -1,018	-2%	-$52.8K	0.03%	581
2019 Q1	$3.7M	Buy	66,985 +907	+1%	+$48K	0.03%	533
2018 Q4	$3.11M	Buy	66,078 +529	+0.8%	+$27.2K	0.03%	518
2018 Q3	$3.9M	Sell	65,549 -197	-0.3%	-$11.5K	0.03%	468
2018 Q2	$3.23M	Hold	65,746	–	–	0.03%	503
2018 Q1	$3.23M	Buy	65,746 +186	+0.3%	+$9.49K	0.03%	503
2017 Q4	$3.09M	Buy	65,560 +6,736	+11%	+$316K	0.03%	520
2017 Q3	$2.94M	Buy	58,824 +1,486	+3%	+$70.5K	0.03%	478
2017 Q2	$2.62M	Buy	57,338 +14,811	+35%	+$639K	0.03%	486
2017 Q1	$1.8M	Buy	42,527 +6,224	+17%	+$261K	0.02%	611
2016 Q4	$1.41M	Buy	36,303 +27,750	+324%	+$1.12M	0.02%	673
2016 Q3	$359K	Buy	8,553 +381	+5%	+$15.6K	0.01%	1372
2016 Q2	$302K	Buy	8,172 +50	+0.6%	+$1.96K	﹤0.01%	1406
2016 Q1	$310K	Sell	8,122 -481	-6%	-$18.7K	0.01%	1317
2015 Q4	$435K	Buy	8,603 +1,011	+13%	+$50K	0.01%	1101
2015 Q3	$346K	Buy	7,592 +1,238	+19%	+$69.2K	0.01%	1162
2015 Q2	$370K	Sell	6,354 -653	-9%	-$37.3K	0.01%	1213
2015 Q1	$386K	Sell	7,007 -348	-5%	-$18.8K	0.01%	1177
2014 Q4	$370K	Buy	7,355 +1,457	+25%	+$71.3K	0.01%	1076
2014 Q3	$273K	Buy	5,898 +58	+1%	+$2.61K	0.01%	1063
2014 Q2	$255K	Sell	5,840 -7,647	-57%	-$310K	0.01%	1068
2014 Q1	$561K	Sell	13,487 -68	-0.5%	-$2.91K	0.02%	682
2013 Q4	$502K	Buy	13,555 +9,399	+226%	+$337K	0.02%	686
2013 Q3	$146K	Buy	4,156 +1,259	+43%	+$41.7K	﹤0.01%	1173
2013 Q2	$84K	Buy	+2,897	New	+$82.4K	﹤0.01%	1406

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PBE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Invesco Biotechnology & Genome ETF (PBE) stake by 0.34% in Q4 2019, buying an estimated $11.7K and bringing the position to 66,345 shares worth $3.71M. The position accounts for 0.02% of the portfolio, ranked #598.

Ladenburg Thalmann Financial Services first reported a position in PBE in Q2 2013 and has held it in 27 quarters since. The position peaked at $3.9M in Q3 2018. 78 funds tracked by Wall St. Rank hold PBE as of Q4 2019.

Ladenburg Thalmann Financial Services held 66,345 shares of Invesco Biotechnology & Genome ETF worth $3.71M as of Q4 2019.
Ladenburg Thalmann Financial Services bought 225 Invesco Biotechnology & Genome ETF shares in Q4 2019, an estimated $11.7K.
Invesco Biotechnology & Genome ETF made up 0.02% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #598 holding.
Ladenburg Thalmann Financial Services first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 27 quarters since.
Ladenburg Thalmann Financial Services's Invesco Biotechnology & Genome ETF position peaked at $3.9M in Q3 2018.
78 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.